Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

3SBio Files to Begin Trial of Anemia Drug

publication date: Jan 8, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio Inc. applied to the SFDA to begin a registrational clinical trial for Feraheme™ (ferumoxytol) Injection, an IV treatment for iron deficiency anemia in patients with chronic kidney disease. 3SBio licensed the China rights for the drug from AMAG Pharmaceuticals last May, shortly before AMAG was granted approval for the product by the US FDA. More details...

Stock Symbols: (NSDQ: SSRX) (NSDQ: AMAG)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Investor Forum
2013-Shanhai
September 4-5,2013
Shanghai, China

ChinaBio® Leadership Retraet
2013-Suzhou
October 24-25, 2013
Suzhou, China

ChinaBio® Investor Forum
2013-Wuhan
December 4-5,2013
Wuhan, China
>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

China Forum 2013
November 3, 2013
Vienna, Austria

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners